Nuvectis Pharma's Ciprocopan Receives Marketing Approval From National Medicinal Products Administration Of China To Treat Paroxysmal Nocturnal Hemoglobinuria

Benzinga · 4d ago

Nuvectis Pharma, Inc. (NASDAQ:NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that ciprocopan (NXP100), a once-daily oral complement Factor B inhibitor, received marketing approval from the National Medicinal Products Administration of China (NMPA) for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) previously untreated with Complement inhibitors (treatment naive).